GlaxoSmithKline Upgraded to “Neutral” at JP Morgan (GSK)
JP Morgan reported on Wednesday that it has upgraded healthcare company GlaxoSmithKline plc (GSK).
The firm has raised its rating on GSK to “Neutral” as analysts see upcoming catalysts balancing out risk.
GlaxoSmithKline shares were up 29 cents, or 0.56%, during pre-market trading Wednesday. The stock is up 20% YTD.
The Bottom Line
Shares of GlaxoSmithKline plc (GSK) have a 4.25% yield based on Tuesday’s closing price of $52.01.
GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability